Kajian Literatur Pengobatan Tuberkulosis Paru dan Efek Samping Obat Antituberkulosis di Indonesia

Literature Review of Treatment of Pulmonary Tuberculosis and the Antitubercular Drug’s Side Effect in Indonesia

Authors

  • Andi Sri Wahyu Ningsih Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia
  • Adam M. Ramadhan Laboratorium Penelitian dan Pengembangan Kefarmasian "Farmaka Tropis"?, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia
  • Dewi Rahmawati Laboratorium Penelitian dan Pengembangan Kefarmasian "Farmaka Tropis"?, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia

DOI:

https://doi.org/10.25026/mpc.v15i1.647

References

[1] WHO, Global Tuberculosis Report 2021. Geneva: World Health Organization, 2021. [Online]. Available: http://apps.who.int/bookorders.

[2] Kementerian Kesehatan RI, “Keputusan Menteri Kesehatan Republik Indonesia Nomor HK. 01.07/MENKES/755/2019 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis.” Kementerian Kesehatan RI, Jakarta, Dec. 02, 2019.

[3] Kementerian Kesehatan RI, “Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 tahun 2016 tentang Penanggulangan Tuberkulosis.” 2016.

[4] W. H. Cahyati and T. Maelani, “Karakteristik Penderita, Efek Samping Obat dan Putus Berobat Tuberkulosis Paru,” HIGEIA (Journal Of Public Health Research And Development), vol. 3, no. 4, pp. 625–634, 2019.

[5] Y. Anwar and F. Ayuni, “Analisis Penggunaan Obat Anti Tuberkulosis Pada Pasien Tuberkulosis Paru Kasus Baru Rawat Jalan Di Rumah Sakit Atma Jaya,” Farmasains: Jurnal Ilmiah Ilmu Kefarmasian, vol. 3, no. 1, pp. 31–34, 2016.

[6] E. Suarni, Y. Rosita, and V. Irawanda, “Implementasi Terapi DOTS (directly observed treatment short-course) pada TB paru di RS Muhammadiyah Palembang,” Syifa’MEDIKA: Jurnal Kedokteran dan Kesehatan, vol. 3, no. 2, pp. 128–136, 2019.

[7] D. A. S. Permana and A. F. Yanti, “Gambaran Dan Analisis Kesesuaian Pengobatan Tuberkulosis Paru Pada Pasien Dewasa Di Puske S Mas Cilacap Selatan Tahun 2018,” Pharmaqueous?: Jurnal Ilmiah Kefarmasian, vol. 1, no. 1, 2019, doi: 10.36760/jp.v1i1.27.

[8] M. Safitri, H. Suryatno, and R. P. Suminar, “Evaluasi Kepatuhan Penggunaan Obat Pada Pasien Tuberkulosis Paru Kategori 1 Di Rsau Dr. M. Salamun Tahun 2020,” Jurnal Kesehatan Aeromedika, vol. 7, no. 2, pp. 28–35, 2021.

[9] T. Anuku, D. Pareta, J. Kanter, and S. Untu, “Evaluasi Rasionalitas Penggunaan Obat Antituberkulosis Pada Pasien Tuberkulosis Paru di Puskesmas IBU Kabupaten Halmahera Barat,” Biofarmasetikal Tropis, vol. 3, no. 1, pp. 101–107, 2020.

[10] D. Masrifah, Y. D. Andarini, and N. M. Kusumaningtyas, “Evaluasi Penggunaan Obat Anti Tuberkulosis Pada Pasien Tuberkulosis Rawat Jalan Di RSUD Kabupaten Caruban Periode Januari-Maret 2018,” Pharmaceutical Jurnal of Islamic Pharmacy, vol. 4, no. 1, 2020.

[11] N. Qiyaam, N. Furqani, and D. J. Hartanti, “Evaluasi Penggunaan Obat Antituberkulosis (OAT) Pada Pasien Tuberkulosis Paru di Puskesmas Kediri Lombok Barat Tahun 2018.,” Lumbung Farmasi: Jurnal Ilmu Kefarmasian, vol. 1, no. 1, 2020, doi: 10.31764/lf.v1i1.1197.

[12] H. Basir and Z. Thahir, “Evaluasi Penggunaan Obat Tuberkulosis Pada Pasien Rawat Jalan Dengan Diagnosa Tuberkulosis Paru Di Klinik Rakyat Kota Makassar Tahun 2019,” Jurnal Kesehatan Yamasi Makassar, vol. 5, no. 1, pp. 50–60, 2021.

[13] O. N. Putra, W. Kartikasari, and A. K. Faizah, “The Correlation Between Acid Fast Bacilli of The Intensive and Continuation Phase in Pulmonary Tuberculosis Patients’category 1,” Jurnal Farmasi Sains dan Praktis, vol. 7, no. 1, pp. 81–88, 2021.

[14] Z. Zulfikri and N. Ainun, “Rasionalitas Penggunaan Obat Tuberkulosis Paru Di Puskesmas Pangkalan Susu Kabupaten Langkat Sumatera Utara,” Forte Journal, vol. 1, no. 2, pp. 127–133, 2021.

[15] N. A. Ismaya, R. Andriati, A. Aripin, T. O. Ratnaningtyas, and F. Tafdhiila, “Rasionalitas Obat Anti Tuberkulosis Pada Pasien Tb Paru Rawat Inap Di Rumah Sakit Umum Kota Tangerang Selatan,” Edu Masda Journal, vol. 5, no. 2, pp. 125–135, 2022.

[16] E. S. Dasopang, F. Hasanah, and C. Nisak, “Analisis Deskriptif Efek Samping Penggunaan Obat Anti Tuberculosis Pada Pasien TBC Di RSUD Dr. Pirngadi Medan,” Jurnal Penelitian Farmasi & Herbal, vol. 2, no. 1, pp. 44–49, 2019.

[17] W. S. Fitri, S. M. Munir, and S. Suyanto, “Karakteristik Penderita Tuberkulosis Paru Relaps yang Berobat di Poliklinik Paru Rumah Sakit Umum Daerah Arifin Achmad Provinsi Riau Tahun 2012-2013,” Jurnal Online Mahasiswa Fakultas Kedokteran Universitas Riau, vol. 1, no. 2, pp. 1–14, 2014.

[18] I. Oliviera, F. N. Kholis, and D. Ngestiningsih, “Pola Kejadian Penyakit Komorbid Dan Efek Samping Oat Pada Pasien Tuberkulosis Di Rsup Dr. Kariadi,” Diponegoro Medical Journal (Jurnal Kedokteran Diponegoro), vol. 5, no. 4, pp. 1081–1091, 2016.

[19] A. Abbas, “Monitoring efek samping obat anti-tuberkulosis (OAT) pada pengobatan tahap intensif penderita TB paru di kota makassar,” Journal of Agromedicine and Medical Sciences, vol. 3, no. 1, pp. 19–25, 2017.

[20] M. F. Musdalipah, Eny Nurhikmah, Karmilah, “Efek Samping Obat Anti Tuberkulosis (Oat) Dan Penanganannya Pada Pasien Tuberkulosis (Tb) Di Puskesmas Perumnas Kota Kendari,” Jurnal Imiah Manuntun, vol. 4, no. 1, 2018.

[21] E. P. Pratiwi, E. Rohmawaty, and I. D. Kulsum, “Efek Samping Obat Anti Tuberkulosis Kategori I dan II Pasien Tuberkolosis Paru Dewasa di Rumah Sakit Hasan Sadikin,” Indonesian Journal of Clinical Pharmacy. https://doi. org/10.15416/ijcp, vol. 4, 2018.

[22] T. Wiyati, D. Irawati, and I. I. Budiyono, “Studi Efek Samping Obat Dan Penanganannya Pada Pasien TB Paru Di Puskesmas Melong Asih, Cimahi,” Jurnal Sains Dan Teknologi Farmasi Indonesia, vol. 3, no. 1, 2018.

[23] A. K. Anam, “tuberculosis, efek samping, Ota Keluhan Penderita Tuberculosis Tentang Efek Samping Obat Anti Tuberculosis Dan Faktor Yang Mempengaruhinya Di Uptd Kesehatan,” Jurnal Keperawatan Malang, vol. 3, no. 2, pp. 85–93, 2018.

[24] R. Rosamarlina et al., “Monitoring Efek Samping Obat Anti Tuberkulosis di Poli TB DOTS RSPI Prof. Dr. Sulianti Saroso,” The Indonesian Journal of Infectious Diseases, vol. 5, no. 2, 2019, doi: 10.32667/ijid.v5i2.81.

[25] S. I. Setiawan and P. Ascobat, “Adverse reactions to first-line anti-tuberculosis drugs as a risk factor of pulmonary tuberculosis treatment default in Jakarta, Indonesia,” Int J Appl Pharm, vol. 11, pp. 80–83, 2019.

[26] T. Ningrum and M. Rahmi, “DESKRIPSI EFEK SAMPING OBAT ANTI TB PADA PASIEN TB YANG SEDANG MENJALANI PENGOBATAN TB DI PUSKESMAS HARAPAN RAYA PEKANBARU,” Jurnal Keperawatan Abdurrab, vol. 4, pp. 60–65, Jul. 2020, doi: 10.36341/jka.v4i1.1298.

[27] A. D. Fraga, N. Oktavia, and R. A. Mulia, “Evaluasi Penggunaan Obat Anti Tuberkulosis Pasien Baru Tuberkulosis Paru di Puskesmas Oebobo Kupang Tahun 2020,” Jurnal Farmagazine, vol. 3, no. 1, 2021.

[28] S. Amal, H. Hidayah, and A. Cahyadi, “Studi Farmakovigilans Terhadap ADRs Obat Antituberkulosis Pada Pasien TB Paru Di Rumah Sakit ‘X’karawang,” Pharma Xplore: Jurnal Sains dan Ilmu Farmasi, vol. 6, no. 1, pp. 11–22, 2021.

[29] T. K. Bakri, R. Akmal, A. Vonna, and F. Sari, “The Impact Of Adverse Drug Reaction Occurrence To Drug Adherence Level: A Cross-Sectional Study In Patients With Tuberculosis,” 2021.

[30] E. W. Savitri, U. Sius, and M. Sudarso, “Hubungan efek samping OAT dengan motivasi pasien TB paru untuk melanjutkan pengobatan,” Holistik Jurnal Kesehatan, vol. 15, no. 3, pp. 391–404, 2021.

[31] O. N. Putra, A. Y. N. Hidayatullah, N. Aida, and F. Hidayat, “Evaluation Of Health–Related Quality Of Life In Pulmonary Tuberculosis Patients Using Short Form-36,” Jurnal Ilmiah Farmako Bahari, vol. 13, no. 1, 2022.

[32] Kemenkes, Pedoman Nasional Pengendalian Tuberkulosis 2014. 2014.

[33] T. dkk Irianti, Mengenal Anti-Tuberkulosis. 2016.

[34] V. Gerdan, N. Akkoç, E. Ucan, and S. Bulac, “Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia,” Singapore Med J, vol. 54, May 2013, doi: 10.11622/smedj.2013097.

[35] H. Kenward, L. Pelligand, K. Savary-Bataille, and J. Elliott, “Nausea: Current knowledge of mechanisms, measurement and clinical impact,” Veterinary Journal, vol. 203, no. 1. 2015. doi: 10.1016/j.tvjl.2014.10.007.

[36] F. Imam et al., “Adverse drug reaction prevalence and mechanisms of action of first-line anti-tubercular drugs,” Saudi Pharmaceutical Journal, vol. 28, no. 3, pp. 316–324, 2020, doi: https://doi.org/10.1016/j.jsps.2020.01.011.

[37] M. Griffiths, D. Makmun, and R. R. Pribadi, Crash Course Gastrointestinal System, Hepatobiliary and Pancreas - 1st Indonesian Edition. Elsevier Health Sciences, 2019. [Online]. Available: https://books.google.co.id/books?id=xiD3DwAAQBAJ

[38] V. Ramappa and G. P. Aithal, “Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management,” Journal of Clinical and Experimental Hepatology, vol. 3, no. 1, pp. 37–49, Mar. 2013, doi: 10.1016/j.jceh.2012.12.001.

[39] F. Yakar, N. Yildiz, A. Akdeniz, and Z. Kilicaslan, “Isoniazid- and rifampicin-induced thrombocytopenia,” Multidiscip Respir Med, vol. 8, p. 13, Feb. 2013, doi: 10.1186/2049-6958-8-13.

[40] L. Kayal, S. Jayachandran, and K. Singh, “Idiopathic thrombocytopenic purpura,” Contemp Clin Dent, vol. 5, no. 3, pp. 410–414, Jul. 2014, doi: 10.4103/0976-237X.137976.

[41] D. J. Girling and K. L. Hitze, “Adverse reactions to rifampicin,” Bull World Health Organ, vol. 57, no. 1, p. 45, 1979.

[42] C. F. Harlow, J. Meghji, L. Martin, T. Harris, and O. M. Kon, “Republished: Rifampicin induced shock during re-exposure for treatment of latent tuberculosis,” Drug and Therapeutics Bulletin, vol. 58, no. 10, p. 157, Oct. 2020, doi: 10.1136/dtb.2020.232117rep.

[43] N. Daniati, K. Kusdiantoro, L. Wulandari, N. Mauthia, and L. Agustini, “The Effect of Zinc Distribution for New TB Patients who Have Ethambutol Therapy Toward Visual Field Defect,” Ophthalmologica Indonesiana, vol. 42, no. 3, Dec. 2016, doi: 10.35749/journal.v42i3.115.

[44] I. Adriztina, A. Adnan, T. Siti Hajar Haryuna, P. Siagian, and S. Sarumpaet, “Gangguan Pendengaran dan Keseimbangan pada Penderita Tuberkulosis yang Mendapat Pengobatan Antituberkulosis Kategori 1 dan 2,” Kesmas: Jurnal Kesehatan Masyarakat Nasional, vol. 8, p. 430, May 2014, doi: 10.21109/kesmas.v8i8.416.

[45] A. Ain, S. Sayekti, and D. Prasetyaningati, “Gambaran Indeks Eritrosit Pada Penderita Tuberkulosis (TBC) Paru Pada Usia 15-55 Tahun (Studi di Pukesmas Mojoagung, Kabupaten Jombang),” Jurnal Insan Cendekia, vol. 6, pp. 8–12, Mar. 2019, doi: 10.35874/jic.v6i1.526.

[46] G. Sinaga, G. Rambert, and M. Wowor, “Gambaran eritrosit urin pada pasien tuberkulosis paru dewasa di RSUP Prof. Dr. R. D. Kandou Manado,” Jurnal e-Biomedik, vol. 4, Jul. 2016, doi: 10.35790/ebm.4.2.2016.14648.

[47] I. D. Sari, Y. Yuniar, and M. Syaripuddin, “Studi Monitoring Efek Samping Obat Antituberkulosis FDC Kategori 1 Di Provinsi Banten Dan Provinsi Jawa Barat,” Media Penelitian dan Pengembangan Kesehatan, vol. 24, no. 1, 2014, doi: 10.22435/mpk.v24i1.3484.28-35.

[48] J. S. Pramono, N. Noorma, A. L. A. Gandini, and S. Fitriani, “The Effect of Side Effects Tuberculosis Treatment in the Early Stage Towards Compliance with Tuberculosis Patients,” Health Notions, vol. 5, no. 01, pp. 29–32, 2021.

Downloads

Published

2022-05-31

How to Cite

Ningsih, A. S. W., Ramadhan, A. M., & Rahmawati, D. (2022). Kajian Literatur Pengobatan Tuberkulosis Paru dan Efek Samping Obat Antituberkulosis di Indonesia: Literature Review of Treatment of Pulmonary Tuberculosis and the Antitubercular Drug’s Side Effect in Indonesia. Proceeding of Mulawarman Pharmaceuticals Conferences, 15(1), 231–241. https://doi.org/10.25026/mpc.v15i1.647

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>